| Followers | 241 |
| Posts | 15536 |
| Boards Moderated | 1 |
| Alias Born | 03/29/2014 |
Tuesday, December 08, 2015 11:51:12 AM
Now I don't know about you, but I would be pretty angry to find out that someone from Ondra was also sitting on that company's board... and was actually sent by Ondra to work directly with me on how to improve share holder value. This should have been disclosed from the beginning, don't you think?
I'd be especially irritated to find this out AFTER I'd sent Ms. Wolf home with confidential files and shared confidential information with her upon which she'd taken copious notes of.
I don't see how you can say that's unfounded. I'd like to think Neil Woodford agrees with this. If he doesn't, I'd be very interested to find out why.
From Flipper's link:
http://www.leagle.com/decision/In%20FDCO%2020150924A42/Cognate%20Bioservices,%20Inc.%20v.%20Smith
I. BACKGROUND
From 2003 until May 2010, Defendant Alan K. Smith ("Smith") was employed as the CEO of Cognate. (ECF No. 100 at 8.) While employed by Cognate, Smith negotiated a contract between Cognate and MacroCure related to the development of an "immune cell wound-healing product known as `CureXcell.'" (Id.) The relationship between Cognate and MacroCure to develop CureXcell, however, did not come to fruition. Instead, after leaving Cognate, Smith worked as a consultant for MacroCure on the development of CureXcell. (Id.) Cognate alleges that while Smith worked as a consultant for MacroCure, he accessed Cognate's computer systems without authorization and copied Cognate's proprietary materials, which he then produced to MacroCure. (Id. at 9.)
The original complaint that Cognate filed on June 19, 2013 named two defendants: Smith and Alan Smith Consulting, Inc.2 (ECF No. 1.) On May 27, 2014, Cognate sought leave to file an amended complaint that, among other things, named MacroCure as a defendant. (ECF No. 36.) On June 9, 2014, while Cognate's motion for leave to file an amended complaint was pending, the Court granted Cognate's motion for the issuance of a letter of request pursuant to the Hague Convention on the Taking of Evidence Abroad in Civil or Commercial Matters. (ECF Nos. 37 & 42.) The Court's Letter of Request (ECF No. 42) sought the assistance of the Israeli Directorate of Courts (the "Israeli court") in obtaining certain discovery from MacroCure, which has its principal place of business in Israel, related to Smith's work for MacroCure. In general, the Letter of Request seeks documents and information in the possession of MacroCure that are likely to show whether Smith improperly accessed Cognate's computer systems, misappropriated Cognate's proprietary materials, and communicated Cognate's proprietary materials to MacroCure. (See ECF No. 145.)
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
